医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dassault Systèmes’ 3DEXPERIENCE Platform Adopted by Olympus Technologies Singapore to Accelerate Medical Device Time to Market

2012年12月18日 PM05:25
このエントリーをはてなブックマークに追加


 

SINGAPORE

Dassault Systèmes (Euronext Paris: #13065, DSY.PA) (Paris:DSY), the 3DEXPERIENCE Company, world leader in 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions, today announced that Olympus Technologies Singapore Pte Ltd, a leading endoscope manufacturer, has selected Dassault Systèmes’ 3DEXPERIENCE platform for the development of its medical devices. The new “Licensed to Cure” industry solution experience will be deployed to create a single environment, allowing to eliminate scattered processes and data, and to “embed” regulations as an asset, optimizing quality and compliance.

Olympus Technologies Singapore has standard operating procedures in developing engineering and software system documentation for their medical device manufacturing. “Licensed to Cure” will help them simplify those procedures by providing a single source of information to always get relevant, up-to-date information and establish true collaboration with the same, accurate set of product data. In addition, Olympus Technologies Singapore will be able to reduce new product time to market and streamline regulatory filings by creating an end-to-end, traceable and compliant product development process directly linked to quality management.

“Dassault Systèmes’ 3DEXPERIENCE platform gives us centralized control and management of all product lifecycle information, enabling real time sharing and collaboration for all functions,” said Lim HN, managing director, Olympus Technologies Singapore. “Being able to combine engineering, quality, and regulatory compliance business processes, we have moved closer towards becoming the R&D and manufacturing centre of choice for our customers.”

“The shifting financial, regulatory and globalization landscapes faced by medical devices manufacturers really call for a comprehensive business experience that can keep up with complexity, lower cost, quality, and compliance at once,” said Monica Menghini, Executive Vice President, Industry and Marketing, Dassault Systèmes. “ Our new “Licensed to Cure” industry solution experience is exactly meeting this challenge by allowing companies like Olympus Technologies Singapore to manage their business objectives in a complex regulatory environment while meeting consumers’ expectations for safe products.”

For more information on “Licensed to Cure” and all of Dassault Systèmes’ industry solution experiences for Life Sciences: http://www.3ds.com/solutions/life-sciences/overview/

###

About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE Company, provides business and people with virtual universes to imagine sustainable innovations. Its world-leading solutions transform the way products are designed, produced, and supported. Dassault Systèmes’ collaborative solutions foster social innovation, expanding possibilities for the virtual world to improve the real world. The group brings value to over 150,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com.

CATIA, SOLIDWORKS, SIMULIA, DELMIA ENOVIA, GEOVIA, EXALEAD, NETVIBES, 3DSWYM and 3D VIA are registered trademarks of Dassault Systèmes or its subsidiaries in the US and/or other countries.

CONTACT

Dassault Systèmes Press Contacts
Derek Lane (NAM)
derek.lane@3ds.com
+1
(818) 673-2243
or
Elena Fernandez (LATAM)
elena.fernandez@3ds.com
+1
(978) 442-2790
or
Virginie Blindenberg (EMEA)
virginie.blindenberg@3ds.com
+33
(0) 1 61 62 84 21
or
Namrata Gadhok (India)
namrata.gadhok@3ds.com
+91
(124) 457 7100
or
Arnaud Sobrero (AP South)
arnaud.sobrero@3ds.com
+65
6511 7942
or
Grace Mu (China)
grace.mu@3ds.com
+86
10 6536 2288
or
Jahyun Ahn (Korea)
jahyun.ahn@3ds.com
+82
2 3270 7893
or
Yukiko Sato (Japan)
yukiko.sato@3ds.com
+81
3 5442 6445
or
Arnaud Malherbe (CORP/France)
arnaud.malherbe@3ds.com
+33
(0) 1 61 62 87 73

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent